You're beating a dead horse here. 505b2 filing and an ANDA filing are not the same thing. This isnt a pivotal registration study, so they can use whatever insulin they want. halo is showing their concept works in both a human insulin and an insulin analog and to see if there are any advantages to combining with one over the other. They're covering their bases and trying to attract a big partner that already markets insulin.
Market Data 
Markets 
AI
